RESCULA Drug Patent Profile

When do Rescula patents expire, and when can generic versions of Rescula launch?

Rescula is a drug marketed by Sucampo Pharma Llc and is included in one NDA.

The generic ingredient in RESCULA is unoprostone isopropyl. There are four drug master file entries for this compound. Additional details are available on the unoprostone isopropyl profile page.

Summary for RESCULA

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	1
Patent Applications:	1,283
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for RESCULA
DailyMed Link:	RESCULA at DailyMed

Paragraph IV (Patent) Challenges for RESCULA

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
RESCULA	Ophthalmic Solution	unoprostone isopropyl	0.15%	021214	1	2014-05-12

US Patents and Regulatory Information for RESCULA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Sucampo Pharma Llc	RESCULA	unoprostone isopropyl	SOLUTION/DROPS;OPHTHALMIC	021214-001	Aug 3, 2000		DISCN	Yes	No

Expired US Patents for RESCULA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Sucampo Pharma Llc	RESCULA	unoprostone isopropyl	SOLUTION/DROPS;OPHTHALMIC	021214-001	Aug 3, 2000	5,166,178
Sucampo Pharma Llc	RESCULA	unoprostone isopropyl	SOLUTION/DROPS;OPHTHALMIC	021214-001	Aug 3, 2000	5,208,256
Sucampo Pharma Llc	RESCULA	unoprostone isopropyl	SOLUTION/DROPS;OPHTHALMIC	021214-001	Aug 3, 2000	5,212,200

International Patents for RESCULA

See the table below for patents covering RESCULA around the world.

Country	Patent Number	Title	Estimated Expiration
Germany	3876050
African Intellectual Property Organization (OAPI)	9028
Japan	H0571567

Supplementary Protection Certificates for RESCULA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0289349	300135	Netherlands		300135, 20080429, EXPIRES: 20130428
0289349	SPC/GB04/007	United Kingdom		PRODUCT NAME: ISOPROPYL(+)-(Z)-7-((1R,2R,3R,5S)-3,5-DIHYDROXY-2-(3-OXODECYL)CYCLOPENTYL)-5-HEPTENOATE; REGISTERED: CH 55634 01 20010329; UK PL00101/0667 20031112
0289349	C300135	Netherlands		PRODUCT NAME: UNOPROSTONEZUUR, DESGEWENST IN DE VORM VAN EEN ESTER OF EEN ZOUT; NATL REGISTRATION NO/DATE: RVG 28628 20030708; FIRST REGISTRATION: FR 359 911-5 AND 359 912-1 20020917

Market Dynamics and Financial Trajectory for Rescula (Unoprostone Isopropyl)

Last updated: February 4, 2026

Overview of Rescula

Rescula (unoprostone isopropropyl) is an ophthalmic prostaglandin analog developed for lowering intraocular pressure (IOP) in patients with glaucoma or ocular hypertension. Approved by the FDA in 1998, its market presence has been limited relative to competitors like latanoprost and timolol due to narrower indications and market penetration issues.

Market Size and Trends

• Global Glaucoma Treatment Market: Valued at approximately $6 billion in 2022, expected to grow at a CAGR of 4.5% through 2028[1].
• Rescula's Market Share: Estimated below 1% due to limited adoption. The drug competes primarily with generics and more aggressively marketed alternatives.
• Key Drivers: Increasing prevalence of glaucoma (over 76 million globally as of 2020, projected to reach 111 million by 2040[2]) and the demand for alternative therapies for patients intolerant to existing drugs.

Market Dynamics Influencing Rescula

• Competitive Landscape: Dominated by latanoprost, bimatoprost, and travoprost, which hold at least 50% combined market share globally[3]. Their broad indications, extensive marketing, and patent expirations have driven growth.

• Regulatory and Patent Factors: Rescula's patent protection has expired, limiting exclusivity. No significant patent extensions or new formulations have emerged to sustain pricing power.

• Physician Preferences: Preference for once-daily dosing regimens and well-studied side-effect profiles favor competitors. Rescula's twice-daily dosing and less extensive clinical data hinder adoption.

• Pricing and Reimbursement: Rescula's pricing remains competitive with generic alternatives. Reimbursement policies primarily favor drugs with extensive proven efficacy and safety data.

Financial Trajectory Analysis

• Historical Sales Performance: Limited growth post-approval, with annual sales estimates remaining below $10 million globally[4]. Little to no recent uptick in sales due to minimal marketing efforts and competition.

• Future Revenue Potential

  Factor	Impact on Revenue
  Patent and exclusivity	Absent; limits pricing and marketing leverage
  Clinical trial results	No recent data; future trials could influence uptake
  Market expansion	Limited; primarily within ophthalmologist practices
  Competitive innovation	New drugs or formulations could erode market share

• Growth Scenarios

  • Optimistic: Approval of new formulations or combination therapies could revitalize sales, potentially reaching $20 million annually within five years.

  • Pessimistic: Market continues to shift toward established prostaglandin analogs, with Rescula sales stagnating below $5 million globally.

Investment and R&D Outlook

• Current R&D investment in Rescula appears minimal. Developers may prioritize pipeline drugs or new delivery systems, with limited focus on Rescula's reformulation or expanded indications.

Regulatory and Market Barriers

• FDA approval for new formulations or delivery systems would require clinical trials, raising costs without guarantee of market success.
• Market penetration is constrained by existing giant competitors and physician preferences.

Conclusion

Rescula's financial trajectory is limited in scope unless new clinical data, formulations, or indications emerge. The current market dynamics favor drugs with proven efficacy, market exclusivity, and extended patent life. Without strategic repositioning, Rescula's sales remain constrained.

---

Key Takeaways

1. Rescula faces limited market share due to competition, patent expiry, and clinical positioning.
2. The global glaucoma treatment market is expanding but favors established, well-marketed drugs.
3. Future sales depend heavily on new formulations or combination therapies—current sales are minimal.
4. Market barriers include regulatory approvals for new formulations and physician preferences.
5. Stakeholders should weigh high R&D costs against uncertain market returns.

---

FAQs

1. Why has Rescula's sales remained low since approval?
Rescula's limited market share stems from competition with more established prostaglandin analogs, its twice-daily dosing regimen, lack of extensive clinical trials compared to rivals, and patent expiration reducing market exclusivity.

2. Are there plans for reformulating Rescula?
No publicly announced plans. Development of new formulations or combination therapies would require significant R&D investment with uncertain market outcomes.

3. How does Rescula compare to dominant glaucoma drugs?
It offers no significant advantages over drugs like latanoprost, which have longer dosing intervals, more extensive clinical data, and broader physician acceptance.

4. What is Rescula’s potential in emerging markets?
Market penetration remains limited; price sensitivity and competition from generics dominate. Regulatory approvals could open opportunities but are not currently underway.

5. Could Rescula benefit from new indications?
Potential exists if clinical trials demonstrate efficacy in additional ocular conditions, but no such trials are publicly scheduled or ongoing.

---

References

1. MarketWatch. "Global Glaucoma Treatment Market Size, Share & Trends Analysis," 2023.
2. WHO. "Glaucoma," 2020.
3. IQVIA. "Global Ophthalmology Market Data," 2022.
4. EvaluatePharma. "Prescription Drug Sales," 2022.